Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon.

Gogas H, Kirkwood JM, Falk CS, Dafni U, Sondak VK, Tsoutsos D, Stratigos A, Markopoulos C, Pectasides D, Spyropoulou-Vlachou M.

Cancer. 2010 Sep 15;116(18):4326-33. doi: 10.1002/cncr.25211.

2.

Interferon alpha for the adjuvant treatment of cutaneous melanoma.

Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V.

Cochrane Database Syst Rev. 2013 Jun 18;(6):CD008955. doi: 10.1002/14651858.CD008955.pub2. Review.

PMID:
23775773
3.

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM.

N Engl J Med. 2006 Feb 16;354(7):709-18.

4.

Human leukocyte antigen class I and class II allele frequencies and HIV-1 infection associations in a Chinese cohort.

Li S, Jiao H, Yu X, Strong AJ, Shao Y, Sun Y, Altfeld M, Lu Y.

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):121-31.

PMID:
17106278
5.

A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.

Wang E, Zhao Y, Monaco A, Uccellini L, Kirkwood JM, Spyropoulou-Vlachou M, Panelli MC, Marincola FM, Gogas H.

PLoS One. 2012;7(7):e40805. doi: 10.1371/journal.pone.0040805. Epub 2012 Jul 24.

6.

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).

Busse A, Rapion J, Fusi A, Suciu S, Nonnenmacher A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U.

Cancer Immunol Immunother. 2013 Jul;62(7):1223-33. doi: 10.1007/s00262-013-1428-4. Epub 2013 Apr 27.

PMID:
23624802
7.

Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.

Kageshita T, Ishihara T, Campoli M, Ferrone S.

Tissue Antigens. 2005 May;65(5):419-28.

PMID:
15853896
8.

Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy.

Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U.

Cancer. 2001 Jul 15;92(2):369-76.

PMID:
11466692
9.

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.

Kirkwood JM, Richards T, Zarour HM, Sosman J, Ernstoff M, Whiteside TL, Ibrahim J, Blum R, Wieand S, Mascari R.

Cancer. 2002 Sep 1;95(5):1101-12.

10.

Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.

Satzger I, Meier A, Schenck F, Kapp A, Hauschild A, Gutzmer R.

Int J Cancer. 2007 Dec 1;121(11):2562-6.

11.

Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.

Tarhini AA, Lin Y, Zahoor H, Shuai Y, Butterfield LH, Ringquist S, Gogas H, Sander C, Lee S, Agarwala SS, Kirwood JM.

PLoS One. 2015 Jul 20;10(7):e0132745. doi: 10.1371/journal.pone.0132745. eCollection 2015.

12.

Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.

Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, Schulte KW, Ring J, Schadendorf D, Lischner S, Burg G, Dummer R.

J Clin Oncol. 2003 Aug 1;21(15):2883-8.

PMID:
12885805
13.

HLA Class I and II genotype in uveal melanoma: relation to occurrence and prognosis.

Maat W, Haasnoot GW, Claas FH, Schalij-Delfos NE, Schreuder GM, Jager MJ.

Invest Ophthalmol Vis Sci. 2006 Jan;47(1):3-6.

PMID:
16384937
14.

Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon.

Mellado B, Del Carmen Vela M, Colomer D, Gutierrez L, Castel T, Quintó L, Fontanillas M, Reguart N, Domingo-Domènech JM, Montagut C, Estapé J, Gascón P.

J Clin Oncol. 2002 Oct 1;20(19):4032-9.

PMID:
12351601
15.

Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse.

Gale DM, Kiley KE.

Clin J Oncol Nurs. 1998 Jan;2(1):5-10. Review.

PMID:
9481250
16.

High-dose adjuvant interferon therapy for melanoma.

Licata AG.

Dermatol Nurs. 1998 Oct;10(5):334-6.

PMID:
9873271
17.

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.

Grob JJ, Dreno B, de la Salmonière P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang C, Bonerandi JJ.

Lancet. 1998 Jun 27;351(9120):1905-10.

PMID:
9654256
18.

Who benefits most from adjuvant interferon treatment for melanoma?

Gogas H, Abali H, Ascierto PA, Demidov L, Pehamberger H, Robert C, Schachter J, Eggermont AM, Hauschild A, Espinosa E.

Am J Ther. 2015 Jan-Feb;22(1):54-60. doi: 10.1097/MJT.0b013e31829e883d. Review.

PMID:
24176884
19.

Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.

Eggermont AM.

Recent Results Cancer Res. 2000;157:178-89. Review.

PMID:
10857171
20.

Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma.

Dréau D, Foster M, Hogg M, Swiggett J, Holder WD, White RL.

Oncol Res. 2000;12(5):241-51.

PMID:
11417749

Supplemental Content

Support Center